x-cardiac GmbH: Successful MDR Certification for AI Solution in Predicting Postoperative Complications – New Product Generation for Optimized Patient Safety
2.10.2024 06:00:00 CEST | news aktuell GmbH | Press release
Berlin, October 2, 2024
x-cardiac, a leader in AI-based medical devices for the prediction of postoperative complications after cardiac surgery, is pleased to announce the successful MDR (Medical Device Regulation) certification of its new x-cardiac-platform. This certification introduces a completely new generation of products offering state-of-the-art technologies to optimize patient care and safety.
The x-cardiac-platform is an innovative tool in the field of digital biomarkers and is specifically designed to increase patient safety and treatment quality in critical situations. With the successful MDR certification, the platform fulfills the strictest European requirements for safety and performance and thus marks a significant milestone in medical technology.
The new product generation includes two innovative plug-ins: x-c-bleeding and x-c-renal-injury. These plug-ins offer unprecedented support in the detection and treatment of bleeding and kidney damage after major heart surgery.
“With the new product generation, we can offer completely new possibilities for predicting postoperative complications in everyday clinical practice, which we will now increasingly promote beyond Germany, Austria, and Switzerland, also with sales partners,” says Oliver Höppner, CEO of x-cardiac. “With the x-cardiac platform, we are offering users a powerful medical device that can make a lasting difference in patient care. We are looking forward to the upcoming EACTS Annual Summit 2024 (European Association for Cardio-Thoracic Surgery) from October 10-12 in Lisbon, where we plan to present our new product generation to the professional audience.”
Chief Medical Officer Prof. Dr. Alexander Meyer on the new product generation: “The x-cardiac-platform sets new standards in the clinical care of patients by performing local validation of the algorithms for each customer. This enables us to ensure that our solutions are optimally tailored to individual needs and circumstances. Optional fine tuning allows us to customize the models to deliver even more precise results.”
Contact:
Oliver Höppner
x-cardiac GmbH
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Slovak outlet Denník N republishes numerous false allegations about Alisher Usmanov that courts have already held to be unlawful13.3.2026 08:48:33 CET | Press release
(Hamburg, Germany - 12 March 2026) On 11 March 2026, the Slovak news outlet Denník N published an article concerning the alleged efforts of the Slovak government to secure the removal of two Russian nationals from the EU sanctions list. The article contained an extensive passage concerning our client, Mr Alisher Burkhanovich Usmanov. By letter dated 12 March 2026, Denník N was requested, in order to avoid court proceedings, to provide a cease-and-desist undertaking backed by a contractual penalty. “The article was published on the eve of the European Commission’s decision on the extension of the sanctions. It reads as if its authors had taken particular care to assemble, in a single piece, every factual allegation that courts have previously found to be unlawful,” said Mr Usmanov’s lawyer, Joachim Nikolaus Steinhöfel. The article contained a dozen such statements about Alisher Usmanov, even though these very allegations have for years been prohibited, retracted, deleted or corrected in
Ship parades, evening shows and partner region Liverpool The 837th HAMBURG PORT ANNIVERSARY with a top programme11.3.2026 14:02:16 CET | Press release
(Hamburg, 11 March 2026) From 8 to 10 May 2026, Hamburg is celebrating its 837th HAMBURG PORT ANNIVERSARY. The programme includes traditional highlights such as the arrival and departure parades and the unique tugboat ballet, as well as several evening shows and the fascinating fireworks display. The programme will be supplemented by new events on the water and on land. The Big Arrival Parade on Friday, 8 May, at 1:30 p.m. marks the start of the festivities and is always an unforgettable experience: more than 100 impressive ships sail up the Elbe right before the eyes of the spectators. The majestic tall ship, the Norwegian three-masted barque Statsraad Lehmkuhl, is particularly stunning. The floating Elbe stage in front of the Landungsbrücken is THE artistic anchor of the HAMBURG PORT ANNIVERSARY: Elbe in Concert presents visitors with rousing live music and impressive performances, creating a unique atmosphere against the backdrop of the harbour skyline at night. This year’s partner
fiskaltrust Launches Portugal’s only Certified Fiscalisation Middleware and CashBox10.3.2026 08:30:00 CET | Press release
Integration Partners and Commercial Partners can now access the Portuguese market through fiskaltrust's POS System API, covering full AT (Autoridade Tributária e Aduaneira) compliance.
WELEDA x Stella McCartney: Paris Fashion Week / Skin Food: 100 years of loving skin9.3.2026 13:53:38 CET | Press release
Arlesheim, 09th March 2026 During this season’s Paris Fashion Week, WELEDA is backstage at the Stella McCartney show ensuring radiant skin: make-up artists draw specifically on the trusted nurturing power of the WELEDA Skin Food range to prep and prime the runway models’ skin perfectly for make-up and create a natural glow.
Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm5.3.2026 08:54:06 CET | Press release
Aachen, Germany & Yeoju, South Korea, 5 March 2026 – Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will have the exclusive South Korean rights to Qutenza®, a topical, non-systemic, non-opioid patch treatment. In Europe, the product is indicated for the management of peripheral neuropathic pain.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom